MIRANDOLA, Italy – June 4, 2025

The intensive care team at University Hospital Antwerp (UZ Antwerp) in Belgium recently completed their first case using the CBM Lifemotion® ECMO system, supporting a 65-year-old male patient with eCPR who was successfully weaned from VA-ECMO after 14 days of support. The experience provided valuable insights into the system’s usability and performance from both nursing and perfusionist perspectives

The CBM Lifemotion® extracorporeal life support system, designed for ease of use in critical care settings. Its compact and modular design supports high-mobility applications, while the intuitive touchscreen interface provides real-time monitoring of key parameters.

Nursing Team Feedback: User-Friendly and Intuitive

ICU nurses highlighted the system’s user-friendliness, noting that the device is intuitive to operate for both experienced ECMO practitioners and colleagues new to the technology. They described the interface as logical, allowing for quick adjustment of settings and immediate visibility of critical information. The clear, concise monitor and graphical display were especially appreciated, providing a comprehensive overview of the system at a glance. Overall, the nursing team expressed widespread satisfaction, emphasizing that the Lifemotion® system’s clarity and ease of use would make it a valuable addition to their department.

Perfusionist Perspective: Solid Performance and Transport Potential

The perfusionist department observed that the oxygenator delivered a surprisingly low R-value (delta P divided by Flow), a metric closely monitored by the team as it could indicate an oxygenator changeout. Although the system was used near the patient’s weaning phase and not pushed to its operational limits, it performed very well. While no patient transport was conducted in this case, the team expressed confidence in the system’s suitability for transport scenarios, citing its comprehensive parameter overview and portability.

The perfusion team highlighted the growing importance of integrated SvO₂ and hematocrit monitoring in European tender evaluations. They noted that incorporating these capabilities would further strengthen the Lifemotion® system’s position in an increasingly competitive ECMO market and align well with evolving clinical and procurement expectations.

Conclusion

The first clinical use of the CBM Lifemotion® ECMO system at UZ Antwerp, Belgium,  was met with positive feedback from both nursing and perfusionist teams. The device’s intuitive interface, clear visual display, and reliable performance were particularly appreciated, supporting effective care delivery in a complex case.

The insights shared by the team underscore the system’s strong clinical utility and provide valuable direction for ongoing innovation—particularly as CBM continues to evolve features in line with emerging clinical needs and user priorities.

CBM Lifemotion® extends its sincere thanks to the UZ Antwerp team for their trust, collaboration, and constructive input. Their experience contributes meaningfully to the advancement of ECMO technology and best practices in critical care.

All feedback and experiences are shared with the permission of UZ Antwerp and in accordance with the institution’s publicity policies. No personal or patient-identifiable information is included.
This content is intended for professional and informational purposes only. It reflects individual clinician experiences and does not replace clinical guidelines, product labeling, or instructions for use. Device use should always follow CE-marked indications and local protocols.